Streptococcus pneumoniae remains a major cause of infection in both children and adults, annually resulting in significant morbidity and mortality. The past two decades have seen an alarming worldwide increase in the incidence of drug-resistant S. pneumoniae (DRSP). DRSP is now common throughout the United States, and physicians are questioning how best to approach this epidemic. With the introduction of a number of newer antimicrobial agents, the potential for improved preventive measures, and a better understanding of DRSP, the approach to the management of DRSP infections may change greatly in the next few years. In this article we will review the development of DRSP, identify populations at increased risk of exposure to DRSP, address what approaches might be used to limit its spread, and suggest initial empirical therapy when treating patients with pneumonia due to DRSP.
Streptococcus pneumoniae remains a major cause of infection in both children and adults, annually resulting in significant morbidity and mortality. The past two decades have seen an alarming worldwide increase in the incidence of drug-resistant S. pneumoniae (DRSP). DRSP is now common throughout the United States, and physicians are questioning how best to approach this epidemic. With the introduction of a number of newer antimicrobial agents, the potential for improved preventive measures, and a better understanding of DRSP, the approach to the management of DRSP infections may change greatly in the next few years. In this article we will review the development of DRSP, identify populations at increased risk of exposure to DRSP, address what approaches might be used to limit its spread, and suggest initial empirical therapy when treating patients with pneumonia due to DRSP.
Streptococcus pneumoniae remains a common pathogen and was not appreciated until 1967, when Hansman and Bullen [3] recovered a penicillin-resistant S. pneumoniae isolate (MIC, a major cause of morbidity and mortality. S. pneumoniae infections are estimated to cause 500,000 cases of pneumonia, 0.6 mg/mL) from a patient with hypogammaglobulinemia and bronchiectasis. In 1974, the incidence of penicillin resistance 55,000 cases of bacteremia, and 6,000 cases of meningitis annually in the United States [1] . The clinical course of S. pneuin Australia and New Guinea was reported to be 12%; by 1980, it had reached 33% [4, 5] . The authors of these studies had no moniae infections is affected by a number of factors including the site and severity of infection, the underlying health of the explanation for the high incidence of ''penicillin-insensitivity'' in New Guinea but were the first to suggest that both the high patient, and the adequacy of antimicrobial therapy. Therefore, it is not surprising that estimates of mortality are reported to carriage rate for S. pneumoniae and the widespread use of penicillins, especially penicillins that often result in relatively range from õ1% to ú50%.
Initially, all S. pneumoniae isolates were exquisitely susceplow blood levels (injected procaine penicillin and oral penicillin tible to penicillin (MIC, £0.06 mg/mL), and this antibiotic V), might be the cause [4] . In 1977, S. pneumoniae isolates served as the drug of choice. Beginning in the 1960s, however, highly resistant to penicillin (MICs, 4 -8 mg/mL) were reported clinical resistance to penicillin and other agents began to be in South Africa, and in 1978, multidrug-resistant strains (those reported. Today, drug-resistant S. pneumoniae (DRSP) is recresistant to three or more different classes of antimicrobial ognized worldwide. agents) were identified [6] . In this article we will review the development of DRSP, idenPenicillin resistance results from multiple alterations of sevtify populations at risk of exposure to DRSP, address what aperal of the penicillin binding proteins (PBPs) and affects the proaches might be used to limit its spread, and, finally, describe binding affinity of penicillin to these PBPs. These alterations strategies for treating pneumonia when DRSP is of concern.
are due to apparently stable genetic mutations and are chromosomally mediated but do not result in any loss or gain in S. pneumoniae virulence [7, 8] . A majority of penicillin-resisDevelopment of Penicillin-Resistant S. pneumoniae tant S. pneumoniae isolates are of selected serotypes (i.e., 6, Penicillin resistance was first induced in S. pneumoniae by 9, 14, 19, and 23), and this observation along with others Schmidt and Sesler in 1943 [2] after they repeatedly adminissuggests a clonality for some penicillin resistance [9] . tered therapy with low-dose penicillin to mice. However, the S. pneumoniae is defined as penicillin susceptible when the clinical significance of penicillin resistance in S. pneumoniae MIC is £0.06 mg/mL. The nomenclature for penicillin resistance is confusing because different authors have used different terms [10] . In this article, penicillin resistance will be defined as intermediate (Pen-I) when the MIC for S. pneumoniae is However, erythromycin-resistant S. pneumoniae strains are often resistant to clindamycin. Most reports of the incidence of DRSP involve large geonot entirely accurate. For example, resistance to cephalosporins graphical areas, but the incidence of DRSP varies considerably increases in a stepwise fashion with the development of penicilnot only between communities but also within a single commulin resistance and is due to alterations in PBP 2x and 1a. Hownity and even between different types of patients. A recent 10-ever, not all b-lactam agents bind to the same PBPs or bind month study was performed in a single large metropolitan area with the same affinity; therefore, certain b-lactam agents retain of the United States to investigate the prevalence of DRSP activity even when penicillin resistance is present. This is espeamong 431 patients with invasive S. pneumoniae infection [18] . cially true for the penicillins amoxicillin and piperacillin, the The community-wide rate of resistance was reported to be 25%, cephalosporins cefotaxime and ceftriaxone, and imipenem/ but the prevalence of DRSP varied considerably from õ5% to cilastatin, and these agents are frequently active against both one-third of isolates, depending on the hospital. The incidence Pen-I and Pen-R isolates.
of DRSP was greatest among white children õ6 years old, a population that frequently receives empirical antimicrobial therapy. The experience with DRSP to date suggests that if the Development of Resistance to Other Antimicrobials present approach to managing these infections continues, DRSP will almost certainly become common throughout the United The increasing incidence of penicillin-resistant S. pneumonStates and that even in communities where DRSP remains iae has been paralleled by an increase in resistance to other uncommon, resistance may develop rapidly [8] . This circumclasses of antimicrobial agents. A recent Centers for Disease stance underscores the importance of continuous surveillance Control and Prevention (CDC) study of the drug susceptibility of the incidence of DRSP, especially among specific populaof clinical S. pneumoniae isolates obtained from sterile sites tions at increased risk [19] . and collected from 13 hospitals in 12 states quantified the Several important lessons have been learned about the DRSP extent of DRSP in a large geographical area. Of the 544 isoepidemic. First, excessive selective pressure, especially when lates, 16.4% were resistant to at least one of the nine antibiotics associated with the empirical use of antibiotics (i.e., treatment tested. Penicillin resistance was noted in 6.6% of isolates, inof upper respiratory and otitis infections in children), and close cluding 1.3% of isolates that were Pen-R. Most penicillinexposure to carriers appear to be the major causes for the resistant S. pneumoniae isolates were resistant to at least one development of DRSP [10] . Second, the incidence of DRSP additional class of antimicrobial agents, and 5.9% of all isolates can increase rapidly, eventually resulting in a high prevalence were identified as multidrug-resistant S. pneumoniae (MRSP) of the organism. In some countries 70% of isolates are reported [14] . This finding suggests that penicillin resistance serves as to be DRSP [20] . Finally, resistance to other antibiotics and a marker of resistance to other drugs. the incidence of MRSP frequently parallel the incidence of The incidence of erythromycin resistance is reported to be penicillin resistance [18] . as high as 19% in the United States [15] . Resistance may Identification of Drug-Resistant S. pneumoniae in develop because of modifications of the ribosome or the presPatients with Pneumonia ence of a macrolide efflux system. S. pneumoniae strains that are resistant to erythromycin are also considered resistant to all One of the most important factors affecting outcome for patients with infections is the rapid introduction of appropriate other macrolides; however, because the tissue concentrations of The development of DRSP has heightened interest in preventive measures. Presently available polyvalent S. pneumoniae antimicrobial therapy. Unfortunately, despite extensive diagvaccines, which contain capsular polysaccharide from 23 difnostic testing, a causative agent is identified in only Ç50% ferent serotypes/groups, include ú85% of serotypes in which of all cases of pneumonia, and the efficacy of using clinical, penicillin resistance is found. Unfortunately, vaccination rates laboratory, and radiographic findings to determine an etiology have remained low (25% -30%), and the protection afforded (syndromic approach) is also questionable [21, 22] . The perforby vaccination is often incomplete and frequently not lifelong mance of blood cultures probably should be considered for all [28] . Antibody titers are raised in only 60% -70% of persons hospitalized patients with pneumonia. Performing cultures of who are vaccinated, and the antibody response is even less in extrapulmonary sites of infection such as pleural fluid, joint persons ú85 years of age, those who are immunosuppressed, fluid, or the CNS is appropriate when these sites are suspected and those who are asplenic [28, 29] . Because vaccination is of being infected. To date, no large studies have been persubject to these limitations but has minimal side effects, some formed to evaluate the role of sputum gram stain or culture in investigators have suggested revaccination every 6 years and the management of lower respiratory tract infections due to possibly more frequently for persons with potentially limited DRSP, much less to compare their diagnostic accuracy with antibody responses. Spread of DRSP is common in certain that of ''gold-standard techniques'' (i.e., a culture of blood, a settings such as nursing homes, hospitals, and day care centers, transthoracic needle aspirate, or pleural fluid). Clearly, even if which raises the question of whether the workers in these set-S. pneumoniae could reliably be identified by gram staining, tings should also be vaccinated. determining antimicrobial susceptibilities would require that a An effective S. pneumoniae vaccine is not presently available sputum culture be performed, and the sensitivity and specificity for children õ2 years old, a group in which S. pneumoniae of sputum cultures have been questioned by many investigators colonization is common and in which empirical antibiotic ther- [22, 23] .
apy is frequent. Not surprisingly, this population serves as Even when an organism is isolated, antibiotic susceptibility a major reservoir for DRSP. Protein-conjugate vaccines are testing still needs to be performed. The most widely used tests currently being tested in clinical trials, and although these vacfor detecting penicillin resistance are the oxacillin disk diffucines are restricted to a small number of serotypes, the availsion assay and the Etest (AB BIODISK, Solna, Sweden). With ability of an adjuvant vaccine directed against the most comthe oxacillin disk diffusion assay, penicillin resistance is susmon DRSP serotypes could substantially reduce the incidence pected when the zone of inhibition is £19 mm for a 1-mg of S. pneumoniae colonization and infection as well as the need oxacillin disk. Unfortunately, while this test is sensitive, it is for antibiotics. This could have a potentially significant impact not very specific; therefore, it is best used as a screening test.
on the incidence of DRSP. The Etest is more specific but costlier. Both tests require
The spread of S. pneumoniae among nursing home residents 18 -24 hours before results are known. Therefore, early treatand hospitalized patients might be reduced by vigorous adherment of most cases of clinical pneumonia is often necessarily ence to infection control measures including handwashing, limempirical.
ited empirical use of antimicrobial agents, and aggressive monitoring for DRSP. A more detailed discussion on minimizing the impact of DRSP was recently published by the DRSP workPopulations at Increased Risk of Exposure to DRSP ing group [30] . Finally, a reduction in the overprescription and inappropriate Because of the limitations of diagnostic testing, it is important to recognize which patients are at increased risk for use of antimicrobial drugs would be beneficial. Increased rates of antimicrobial use and the development of resistance have exposure to DRSP (table 2) . Obviously, knowing the prevalence of DRSP in the community is important, but even when been well described. Since 1980 antimicrobial use by officebased physicians has increased by 28% for all age groups, and DRSP is rarely isolated, there still may be populations at in-/ 9c4c$$my21 04-10-98 02:07:25 cida UC: CID CID 1998;26 (May) Drug-Resistant S. pneumoniae rates of antibiotic treatment for children õ15 years old are 2 mg/mL. Furthermore, ceftriaxone or cefotaxime would be good alternatives if the MIC of penicillin is higher, but only if the three times as high as the rates for any other age group. Reducing these rates and using antimicrobial therapy more judi-MIC of ceftriaxone or cefotaxime is £2 mg/mL. In the third comparative study by Plouffe et al. [33] , 39 of ciously, especially for infections that are not life-threatening, would be helpful [30] . The CDC is currently in the preliminary 499 clinical S. pneumoniae isolates were classified as DRSP, but only five Pen-R isolates, for which the MICs were §4 phase of developing guidelines. mg/mL, were recovered. The outcomes were similar for subjects infected by DRSP and those infected by susceptible What Is Known Presently Regarding the Treatment of S. pneumoniae, but those infected with DRSP had hospital DRSP Pneumonia?
stays that were a mean of 3.7 days longer. However, no effort to stratify patients on the basis of severity of illness or comorbid Unlike the situation with DRSP meningitis, which has been the subject of considerable clinical research [31] , the informafactors was reported. The results of these three studies are limited because the tion available regarding the proper treatment of DRSP pneumonia is limited. To date, three prospective studies that included studies were neither randomized nor designed to compare antibiotic efficacy. In addition, the incidence of Pen-R S. pneumonlarge numbers of subjects, most or all of whom had S. pneumoniae pneumonia, have been reported. These studies comiae (MIC, §4 mg/mL) was low, and the authors were unable to determine whether high-dose iv penicillin or ceftriaxone or pared the outcomes of treatment of infections caused by penicillin-susceptible, Pen-I, and Pen-R S. pneumoniae. A total of cefotaxime would be effective when the MIC of these drugs reached a level of §4 mg/mL. Finally, the role of resistance Ç1,100 subjects were enrolled, but Pen-R S. pneumoniae isolates were uncommon, and Pen-R isolates for which the MIC to other antimicrobial agents was not evaluated. In addition to these clinical studies, there have been several was §4 mg/mL were rare.
In the first of these three studies, which followed a prospecrecent review articles that have included recommendations on treating DRSP pneumonia [8, 34 - other b-lactam agent at an equivalent dose) was adequate for infections due to Pen-I strains of S. pneumoniae, but for Penwere more common among subjects who were HIV positive or had received antibiotics within the month before enrollment.
R strains, they noted several reports of failure. Patients infected by Pen-R S. pneumoniae frequently had underlying diseases The MIC of penicillin for the one Pen-R strain was §4 mg/mL. The clinical success of antimicrobial therapy was simisuch as cancer, chronic liver disease, or diabetes mellitus, and their conditions might have influenced outcome. Friedland and lar for subjects with Pen-I strains and those with penicillinsusceptible strains. Friedland concluded that Pen-I is not a McCracken recommended using vancomycin or imipenem for patients suspected of being infected with Pen-R S. pneumoniae, significant factor in the treatment of S. pneumoniae pneumonia or occult bacteremia but could not comment on the efficacy of e.g., for debilitated patients with nosocomial pneumonia. These investigators noted that another treatment possibility was an penicillin in treating Pen-R S. pneumoniae infection.
In the second study, which was performed over a 10-year extended-spectrum cephalosporin, but only if its MIC was £8 mg/mL for the infecting strain. period, Pallares et al.
[32] recruited 504 adults who had severe culture-proven S. pneumoniae pneumonia. A total of 412 isoWhile ceftriaxone or cefotaxime have been recommended for treatment of S. pneumoniae infections in certain settings, the lates were recovered from blood samples. Although 145 (29%) of the isolates were either Pen-I or Pen-R, only 65 (13%) were activity of these agents is not shared by all extended-spectrum cephalosporins. For example, the efficacy of ceftizoxime has Pen-R, but the penicillin MIC was not ú4 mg/mL for any of them, and only 6% were cephalosporin resistant. The mortality been questioned by several investigators [37, 38] . In one study that was conducted to evaluate the activity of penicillin, ceftriwas higher among subjects infected with Pen-I or Pen-R isolates than among those infected with penicillin-susceptible axone, cefotaxime, and ceftizoxime against clinical S. pneumoniae isolates, as measured by MICs and time-kill curves, S. pneumoniae (38% vs. 24%, respectively; P Å .001). However, after polymicrobial infections were excluded and prethe authors noted that ''ceftizoxime is far less active than cefotaxime or ceftriaxone against many pneumococcal isolates'' dictors of mortality were adjusted, no significant difference in mortality was found.
[37]. On the basis of these findings, the authors concluded that ''ceftizoxime should not be used to treat proven or suspected Pallares et al. [32] concluded that current levels of S. pneumoniae resistance to penicillin and cephalosporins are not associated pneumococcal infection in areas where resistance to penicillin is prevalent.'' with increased mortality. These investigators stated that highdose intravenous penicillin G (150,000 to 200,000 U/[kgrd])
Mandell [34] suggested that vancomycin might be used in cases of community-acquired pneumonia when infection with might be effective for treating patients with S. pneumoniae pneumonia when the MIC of penicillin ranges from 0.12 mg/mL to Pen-R S. pneumoniae was a concern. Bryant and Salmon [35] / 9c4c$$my21 04-10-98 02:07:25 cida UC: CID suggested that when treating S. pneumoniae empyema, ceftriaccumulate at high concentrations in pulmonary tissue, demonstrate increased activity on a weight basis when compared with axone or cefotaxime be used if the S. pneumoniae isolate was only Pen-I and was cephalosporin susceptible. These investigaolder quinolones such as ofloxacin and ciprofloxacin, and have excellent in vitro activity (MIC, 0.25 mg/mL). The incidence tors recommended that vancomycin be used if the isolate is Pen-R and the MIC is ú4.0 mg/mL. Finally, Strachan and of S. pneumoniae resistance to fluoroquinolones has remained low; therefore, these agents presumably should be effective Friedland [36] stated that although the MIC breakpoint above which penicillin therapy is likely to be ineffective for nonmenin treating DRSP pneumonia [45] . The safety profile of the fluoroquinolones is good, but some fluoroquinolones do affect ingeal infections is unknown, it is probably §4.0 mg/mL. cytochrome P-450, while phototoxicity has been reported as a side effect of others (sparfloxacin).
What Factors Might Change the Present Approach to the
There has been a limited number of clinical trials to deterTreatment of Patients with S. pneumoniae Pneumonia?
mine the efficacy of these newer agents, but several reviews of the early clinical experience with them have recently been A central problem in the management of pneumonia is that in a significant proportion of cases an etiology is not deterpublished. Results of early studies are promising. An analysis of two double-blind randomized trials that included 1,137 mined, and even when a pathogen is isolated, susceptibility results are not available for at least 18 -24 hours. Since a adults hospitalized with community-acquired pneumonia was recently reported; 345 of the cases were caused by S. pneumonpatient's clinical course can be affected by the prompt initiation of appropriate antimicrobial therapy, selecting such therapy is iae [46] . Efficacy was significantly better in the sparfloxacin group than in the comparator group (subjects receiving either of the utmost importance. Therefore, until a rapid and accurate test that is capable of identifying DRSP within a relatively amoxicillin, with or without clavulanic acid, or erythromycin). In this study, the rates of resistance to amoxicillin and to erythshort time (õ6 hours) is developed, initial treatment of pneumonia will continue to be empirical. Unfortunately, such a test romycin were 8% and 5%, respectively. On the basis of these results, the authors concluded that sparfloxacin is an approappears to be years away.
Studies performed to date have shown that the use of highpriate and reliable choice for the empirical treatment of community-acquired pneumonia, regardless of the suspected bacterial dose penicillin or certain cephalosporins is adequate for treating S. pneumoniae pneumonia, regardless of whether the organism pathogen. Nevertheless, while pneumococci are not necessarily penicillin resistant, future trends in susceptibility to fluoroquiis penicillin susceptible or Pen-I [32, 33] . Studies investigating the role of therapy in patients with severe pneumonia, signifinolones will require monitoring, along with post-marketing surveillance for evidence of questionable clinical efficacy, should cant underlying disease, extrapulmonary involvement, or infections caused by Pen-R organisms for which the MIC is §4 more-resistant strains emerge. The results of future clinical trials will be important in determining the role of the new mg/mL or that show increases in resistance to other commonly used antimicrobial agents have yet to be reported. Therefore, fluoroquinolones in treating S. pneumoniae pneumonia. this remains a controversial area. Outcome-based studies in these areas need to be performed before many physicians will Approach to the Treatment of Adults with Pneumonia feel comfortable using high-dose penicillin or certain cephalosporins in these settings.
In determining appropriate antimicrobial therapy, it is important to remember that the clinical presentation and the viruPresently, because of fear of inducing resistance both in S. pneumoniae and enterococci, empirical use of vancomycin lence of DRSP do not differ from those of susceptible strains of S. pneumoniae and that susceptibility results from any culis discouraged, and it is often strictly reserved for special situations. Newer antibiotics that are effective against DRSP infecture will not be available for at least 24 hours. Guidelines for treating both community-acquired pneumonia (CAP) [22] and tions are either just now becoming available or are in phase 3 trials. The availability of several new drugs or classes of drugs hospital-acquired pneumonia (HAP) [23] in immunocompetent adults have recently been published. In both sets of guidelines, may dramatically alter the empirical treatment of pneumonia in cases where DRSP is a concern. These classes include new initial antibiotic choices were empirical. For patients with CAP, antimicrobial choices were based on the most likely pathogen, fluoroquinolones, the streptogramins, and totally new classes of antibiotics such as the oxizolidinones [11, 39 -41] .
according to specific groups of patients. These groups were defined by the presence of certain clinical factors including age Despite low levels of fluoroquinolone resistance, use of older fluoroquinolones (ciprofloxacin or ofloxacin) in treating and the presence of comorbid disease (congestive heart failure, chronic obstructive pulmonary disease, structural lung disease, S. pneumoniae pneumonia has been discouraged by a lack of clinical studies and reports of clinical failures [42, 43] . This chronic renal insufficiency, or liver failure) and the severity of illness. For patients with HAP, antimicrobial choices were area remains controversial because there are publications supporting the use of older fluoroquinolones [21, 44] . The newerguided by the most likely pathogen in specific patient groups on the basis of the severity of illness, presence of specific risk generation fluoroquinolones such as sparfloxacin and levofloxacin have been best studied. These newer fluoroquinolones factors for certain pathogens, and length of hospital stay before / 9c4c$$my21 04-10-98 02:07:25 cida UC: CID [22, 23] . † Assumes that the prevalence of Pen-R isolates in the community is low. ‡ Assumes a low prevalence of macrolide resistance in the community; if the incidence of macrolide resistance is high, consider a fluoroquinolone (see text). § With additional risk factors, other agents should be added [23] .
the development of pneumonia. The authors of both sets of Certain diagnostic studies should be considered for all hospitalized patients with pneumonia. These studies include blood guidelines recognized that antibiotic choices might need to be modified on the basis of local resistance patterns. Concerns cultures, chest radiographs (preferably posteroanterior and lateral), and certain laboratory tests. It is helpful to perform blood over DRSP were not specifically addressed in either study.
Because of the increasing incidence of DRSP, some modificultures, since they can identify the infecting pathogen, or if negative, suggest a less severe process. Findings on a chest cation of these guidelines is in order (table 3) . The recommendations regarding diagnostic testing in both guidelines probably radiograph can indicate other noninfectious or infectious causes of disease (e.g., cancer or tuberculosis), more severe illness remain the same. Whether additional testing should be performed when DRSP might be a concern is presently unknown.
(multilobar infiltrates), or the presence of pleural effusions and lung abscesses, which would influence therapy. Laboratory test Diagnostic testing is justified in the treatment of certain patient populations, not only to identify a specific pathogen but also results can indicate organ dysfunction and severe hypoxemia. To treat CAP in the outpatient setting, the age of the patient to stratify for severity of illness. The results of large studies in which intensive diagnostic testing was performed suggest (£60 years or ú60 years) and the presence of underlying disease should be considered in determining appropriate empirthat not all tests are necessary. For example, results from serological testing are often unavailable for weeks, long after a ical antibiotic therapy. If a patient is young and does not have comorbid disease, then the current recommendations of a macpatient has either recovered or died of the infection. In addition, diagnostic testing for patients with pneumonia who are treated rolide or a tetracycline are appropriate. For smokers, one of the newer macrolides is recommended. These agents offer a in an outpatient setting is frequently very limited because it is expensive and because the tests rarely alter management except broad spectrum of activity that covers the most common organisms, they are effective for empirical treatment when the risk in cases where the diagnosis or severity of pneumonia is in doubt or where pneumonia might be complicated by other for DRSP is low, and adverse outcomes are extremely rare. When resistance to macrolides is common in a community factors (i.e., the patient is a smoker who is at increased risk of cancer).
or a patient is at risk for infection with DRSP, then an oral fluoroquinolone alone or amoxicillin/clavulanate plus a newer possibly clindamycin plus aztreonam should be considered. For patients with severe HAP, coverage must be directed both at macrolide can be used. Older patients (ú60 years) and/or patients with comorbid processes are at increased risk for morbid-P. aeruginosa and Acinetobacter species, as well as the possibility of DRSP; therefore, the addition vancomycin may be ity and mortality. Among older otherwise healthy and stable patients, the risk of infection due to DRSP is low, and amoxicilconsidered. These recommendations should be further expanded on the lin/clavulanate, with or without a macrolide, is usually acceptable therapy. When a comorbid process or more serious CAP basis of additional findings. Because of the limited tissue concentration in the meninges, when meningitis is suspected (rethat does not require hospitalization are present, different antibiotics are required, and amoxicillin/clavulanate, with or withgardless of the severity of pneumonia), there is good evidence to suggest that cefotaxime would be effective unless there is out one of the newer macrolides, or an oral fluoroquinolone alone should be considered. Historically, in this population concern about resistance, in which case vancomycin should be used. Furthermore, the use of vancomycin might be considered £20% of patients initially treated as outpatients ultimately have required hospitalization, but the mortality has been reported to if bacterial pericarditis is suspected; however, the role of vancomycin in treating this type of infection has not been reported. be õ5%.
For hospitalized patients with mild-to-moderate CAP -i.e., The use of vancomycin should be restricted to other sites of infection unless highly resistant DRSP is identified or suspected those usually treated on the ward -intravenous antimicrobial choices include cefotaxime or ceftriaxone or a b-lactam/bor a physician is concerned about the outcome for a patient. lactamase inhibitor like piperacillin/tazobactam, with or without a macrolide, or possibly a fluoroquinolone alone. If higher Summary levels of Pen-R (MIC, §4 mg/mL) is a concern, then imipenem/ Although there is limited experience in treating infection cilastatin, with or without a macrolide, or a fluoroquinolone due to DRSP, a clearer picture of this epidemic is coming into should be considered. Mortality among hospitalized patients focus. It is appreciated that the incidence of resistant with mild-to-moderate CAP has historically been reported to S. pneumoniae varies considerably throughout the United be 8% -14%.
States, although it is increasingly becoming a country-wide For severe CAP, which usually requires intensive care, the problem; and once DRSP is identified locally, its incidence use of endotracheal aspiration, a protected specimen brush, might increase rapidly. Resistance to penicillin often parallels or bronchoalveolar lavage should be considered for obtaining the development of resistance to other antimicrobial agents, specimens for culture. Endotracheal aspiration, especially for especially in specific groups (table 2). The outcome for patients patients who have not received prior antibiotics, may be helpful infected with DRSP can be improved with the rapid institution in excluding possible pathogens. In addition, a chest radiograph of effective antimicrobial therapy. Intravenous treatment with should be obtained, and blood cultures and cultures of any high-dose penicillin or a third-generation cephalosporin apother clinically apparent sites of infection (i.e., the CNS or pears to be effective in eradicating S. pneumoniae when the pleural fluid) should be performed. If there is concern that the MIC of penicillin is õ4 mg/mL, except where tissue penetration patient might be infected with highly Pen-R S. pneumoniae is low, such as in meninges [30] . When possible, the empirical (MIC, §4 mg/mL), strong consideration should be given to use of vancomycin should be discouraged to prevent the develadministering intravenous therapy that includes vancomycin, opment of resistance. imipenem/cilastatin, or one of the newer fluoroquinolones until While much is understood about the DRSP epidemic, questhe results from diagnostic studies are obtained.
tions remain for which answers are presently unknown and While the diagnostic approach to the patient with HAP is which may affect therapy in the future. These questions are as similar, the treatment of HAP differs from that of CAP. When follows: will the incidence of high-level DRSP accelerate or HAP is present, it is recognized that all patients are at risk of plateau? How high can the MIC for DRSP rise? Does the initial infection by several ''core'' pathogens. These core pathogens use of ineffective therapy while awaiting results of susceptibilinclude S. pneumoniae, Haemophilus influenzae, Staphylococity studies affect outcome and if so in what settings? What will cus aureus, and aerobic gram-negative bacilli but not Pseudobe the role of newer antimicrobial agents in treating pneumomonas aeruginosa or Acinetobacter species. On the basis of nia? And most importantly, can the judicious use of empirical these core pathogens, a set of core antimicrobial agents have therapeutic regimens consisting of newer antimicrobial agents been suggested. Additional antimicrobial agents have been with excellent activity against DRSP, combined with an adjuadded on the basis of other factors, including the severity of vant vaccine for S. pneumoniae, reduce the rate of DRSP? illness, presence of specific risk factors, and length of hospitalization before the development of HAP. When the risk of DRSP infection is significant, then the regimen of these core antimi-
